



Claims

1. A pharmaceutically active compound represented by formula III;



- 5 or a pharmaceutically acceptable salt thereof wherein:
- $X^1 - X^3$  are independently C or N;
- $X^4$  is CH or N, wherein not more than two of  $X^1 - X^4$  is N;
- when  $X^5$  is N,  $R^5$  is a lone pair,  $X^{10}$  is CH and the bond between  $X^5$  and  $X^{10}$  is a double bond;
- 10 when  $X^5$  is CH,  $R^5$  is H,  $X^{10}$  is  $CH_2$  and the bond between  $X^5$  and  $X^{10}$  is a single bond;
- when  $X^5$  is C,  $R^5$  may be defined as below,  $X^{10}$  is CH and the bond between  $X^5$  and  $X^{10}$  is a double bond;
- $X^6 - X^8$  are independently C or N;
- 15  $X^9$  is CH or N, wherein not more than two of  $X^6 - X^9$  is N;
- $R^1 - R^3$  and  $R^6 - R^8$  represent a lone pair or O when each respective  $X^1 - X^3$  and  $X^6 - X^8$  is N; and
- when  $X^1 - X^3$  or  $X^6 - X^8$  is C, each respective  $R^1 - R^3$  and  $R^6 - R^8$  is independently selected from the group consisting of:
- 20 a) H, substituted or unsubstituted C(1-8) alkyl, halogen, azido, cyano, nitro, or  $NR^{21}R^{22}$ , wherein  $R^{21}$  represents H or C(1-8) alkyl, and  $R^{22}$  represents H, substituted or unsubstituted C(1-8) alkylcarbonyl, substituted or unsubstituted arylcarbonyl, heterocycle, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted C(1-8) alkylaminocarbonyl, substituted or unsubstituted
- 25 arylaminocarbonyl;

- b)  $OR^{23}$ , wherein  $R^{23}$  is H, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted arylcarbonyl;
- c)  $SR^{23}$ , wherein  $R^{23}$  is defined as in b);
- d)  $O(CH_2)_j-R^{24}$ ,  $O(CH_2)_j-O-R^{24}$ , or  $O(CH_2)_j-S-R^{24}$ , wherein j is an integer from 1 to 8,  
 5 and  $R^{24}$  is selected from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
- e)  $S(CH_2)_jR^{24}$ ,  $S(CH_2)_j-O-R^{24}$ , or  $S(CH_2)_j-S-R^{24}$ , wherein j and  $R^{24}$  are defined as in d);
- f)  $C\equiv C-R^{25}$ ,  $C\equiv C-OR^{25}$ , or  $C\equiv C-CO_2R^{25}$ , wherein  $R^{25}$  is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- 10 g)  $CH=CH-R^{25}$ ,  $CH=CH-OR^{25}$ , or  $CH=CH-CO_2R^{25}$ , having a stereochemistry of E or Z, and  $R^{25}$  is defined as in f);
- h)  $C\equiv C-NR^{25}R^{26}$  or  $C\equiv CCONR^{25}R^{26}$ , wherein  $R^{25}$  is defined as in f), and  $R^{26}$  is defined as  $R^{25}$ , and  $R^{25}$  and  $R^{26}$  are selected independently;
- i)  $CH=CH-NR^{25}R^{26}$  or  $CH=CHCONR^{25}R^{26}$ , having a stereochemistry of E or Z, wherein  
 15  $R^{25}$  and  $R^{26}$  are independently defined as in h);
- j)  $(CH_2)_kR^{25}$ ,  $(CH_2)_k-COOR^{25}$ , or  $(CH_2)_k-OR^{25}$ , wherein k is an integer from 2 to 6 and  $R^{25}$  is defined as in f);
- k)  $(CH_2)_kNR^{25}R^{26}$ ,  $(CH_2)_kCONR^{25}R^{26}$ , wherein  $R^{25}$  and  $R^{26}$  are selected independently, and  $R^{25}$  and  $R^{26}$  are defined as  $R^{25}$  in f);
- 20 l)  $CH_2XR^{27}$ , wherein X is O or S and  $R^{27}$  is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;
- $R^4$  is selected from the group consisting of:
- m) H, substituted or unsubstituted C(1-8) alkyl;
- n)



wherein  $X=O$ ,  $S$ , or  $NH$ ,  $n=1$  to 4, and  $R^{51}$  is H,  $R^{52}$  and  $R^{53}$  are independently chosen from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system;


- 30  $R^5$  is selected from the group consisting of:

o) a lone pair when  $X^5$  is N;

and when  $X^5$  is C,  $R^5$  is selected from the group consisting of:

p) H, substituted and unsubstituted C(1-8) alkyl;); or


q)



wherein  $X=O$ , S, or NH,  $n=1$  to 4 and  $R^{51}$  is H,  $R^{52}$  and  $R^{53}$  are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system; or

when  $A^1$  and  $A^2$ , and  $B^1$  and  $B^2$ , respectively combine to form oxygen,  $R^1-R^3$  and  $R^5-R^8$  are H, and  $R^4$  is H or  $CH_3$ , at least one of  $X^1-X^9$  represents a ring member other than carbon.

2. A pharmaceutically active compound represented by formula I;



or a pharmaceutically acceptable salt thereof wherein:

$X^1-X^3$  are independently C or N;

$X^4$  is CH or N, wherein not more than two of  $X^1-X^4$  is N;


$X^6-X^8$  are independently C or N;

$X^9$  is CH or N, wherein not more than two of  $X^6-X^9$  is N;

$R^1-R^3$  and  $R^6-R^8$  represent a lone pair or O when each respective  $X^1-X^3$  and  $X^6-X^8$  is N; and

when  $X^1 - X^3$  or  $X^6 - X^8$  is C, each respective  $R^1 - R^3$  and  $R^6 - R^8$  is independently selected from the group consisting of:

- a) H, substituted or unsubstituted C(1-8) alkyl, halogen, azido, cyano, nitro, or  $NR^{21}R^{22}$ , wherein  $R^{21}$  represents H or C(1-8) alkyl, and  $R^{22}$  represents H, substituted or unsubstituted C(1-8) alkylcarbonyl, substituted or unsubstituted arylcarbonyl, heterocycle, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted C(1-8) alkylaminocarbonyl, substituted or unsubstituted arylaminocarbonyl;
  - b)  $OR^{23}$ , wherein  $R^{23}$  is H, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted arylcarbonyl;
  - c)  $SR^{23}$ , wherein  $R^{23}$  is defined as in b);
  - d)  $O(CH_2)_jR^{24}$ ,  $O(CH_2)_j-O-R^{24}$ , or  $O(CH_2)_j-S-R^{24}$ , wherein j is an integer from 1 to 8, and  $R^{24}$  is selected from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
  - e)  $S(CH_2)_jR^{24}$ ,  $S(CH_2)_j-O-R^{24}$ , or  $S(CH_2)_j-S-R^{24}$ , wherein j and  $R^{24}$  are defined as in d);
  - f)  $C\equiv C-R^{25}$ ,  $C\equiv C-OR^{25}$ , or  $C\equiv C-CO_2R^{25}$ , wherein  $R^{25}$  is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
  - g)  $CH=CH-R^{25}$ ,  $CH=CH-OR^{25}$ , or  $CH=CH-CO_2R^{25}$ , having a stereochemistry of E or Z, and  $R^{25}$  is defined as in f);
  - h)  $C\equiv C-NR^{25}R^{26}$  or  $C\equiv CCONR^{25}R^{26}$ , wherein  $R^{25}$  is defined as in f), and  $R^{26}$  is defined as  $R^{25}$ , and  $R^{25}$  and  $R^{26}$  are selected independently;
  - i)  $CH=CH-NR^{25}R^{26}$  or  $CH=CHCONR^{25}R^{26}$ , having a stereochemistry of E or Z, wherein  $R^{25}$  and  $R^{26}$  are independently defined as in h);
  - j)  $(CH_2)_kR^{25}$ ,  $(CH_2)_k-COOR^{25}$ , or  $(CH_2)_k-OR^{25}$ , wherein k is an integer from 2 to 6 and  $R^{25}$  is defined as in f);
  - k)  $(CH_2)_kNR^{25}R^{26}$ ,  $(CH_2)_kCONR^{25}R^{26}$ , wherein  $R^{25}$  and  $R^{26}$  are selected independently, and  $R^{25}$  and  $R^{26}$  are defined as  $R^{25}$  in f);
  - l)  $CH_2XR^{27}$ , wherein X is O or S and  $R^{27}$  is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;
- $R^4$  is selected from the group consisting of:
- m) H, substituted or unsubstituted C(1-8) alkyl;
  - n)



wherein  $X=O$ ,  $S$ , or  $NH$ ,  $n=1$  to  $4$ , and  $R^{51}$  is  $H$ ,  $R^{52}$  and  $R^{53}$  are independently chosen from the group consisting of  $H$ , alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl, substituted

5 heteroalkyl, heteroaryl, or substituted heteroaryl ring system;


$R^5$  is selected from the group consisting of:

o) a lone pair when  $X^5$  is  $N$ ;

and when  $X^5$  is  $C$ ,  $R^5$  is selected from the group consisting of:

p)  $H$ , substituted and unsubstituted  $C(1-8)$  alkyl;); or

10 q)




wherein  $X=O$ ,  $S$ , or  $NH$ ,  $n=1$  to  $4$  and  $R^{51}$  is  $H$ ,  $R^{52}$  and  $R^{53}$  are independently chosen from the group consisting of  $H$ , substituted or unsubstituted  $C(1-8)$  alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl,

15 substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system; or

wherein in formula I, when  $A^1$  and  $A^2$ , and  $B^1$  and  $B^2$ , respectively combine to form oxygen,  $R^1-R^3$  and  $R^5-R^8$  are  $H$ , and  $R^4$  is  $H$  or  $CH_3$ , at least one of  $X^1 - X^9$  represents a ring member other than carbon.

20 3. A pharmaceutically active compound represented by formula II;



II

or a pharmaceutically acceptable salt thereof wherein:

$X^1 - X^3$  are independently C or N;

$X^4$  is CH or N, wherein not more than two of  $X^1 - X^4$  is N;

5  $X^6 - X^8$  are independently C or N;


$X^9$  is CH or N, wherein not more than two of  $X^6 - X^9$  is N;

$R^1 - R^3$  and  $R^6 - R^8$  represent a lone pair or O when each respective  $X^1 - X^3$  and  $X^6 - X^8$  is N; and


10 when  $X^1 - X^3$  or  $X^6 - X^8$  is C, each respective  $R^1 - R^3$  and  $R^6 - R^8$  is independently selected from the group consisting of:

- a) H, substituted or unsubstituted C(1-8) alkyl, halogen, azido, cyano, nitro, or  $NR^{21}R^{22}$ , wherein  $R^{21}$  represents H or C(1-8) alkyl, and  $R^{22}$  represents H, substituted or unsubstituted C(1-8) alkylcarbonyl, substituted or unsubstituted arylcarbonyl, heterocycle, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted C(1-8) alkylaminocarbonyl, substituted or unsubstituted arylaminocarbonyl;
- b)  $OR^{23}$ , wherein  $R^{23}$  is H, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted arylcarbonyl;
- c)  $SR^{23}$ , wherein  $R^{23}$  is defined as in b);
- 20 d)  $O(CH_2)_jR^{24}$ ,  $O(CH_2)_jO-R^{24}$ , or  $O(CH_2)_jS-R^{24}$ , wherein j is an integer from 1 to 8, and  $R^{24}$  is selected from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
- e)  $S(CH_2)_jR^{24}$ ,  $S(CH_2)_jO-R^{24}$ , or  $S(CH_2)_jS-R^{24}$ , wherein j and  $R^{24}$  are defined as in d);
- f)  $C\equiv C-R^{25}$ ,  $C\equiv C-OR^{25}$ , or  $C\equiv C-CO_2R^{25}$ , wherein  $R^{25}$  is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

- g)  $\text{CH}=\text{CH}-\text{R}^{25}$ ,  $\text{CH}=\text{CH}-\text{OR}^{25}$ , or  $\text{CH}=\text{CH}-\text{CO}_2\text{R}^{25}$ , having a stereochemistry of E or Z, and  $\text{R}^{25}$  is defined as in f);
- h)  $\text{C}\equiv\text{C}-\text{NR}^{25}\text{R}^{26}$  or  $\text{C}\equiv\text{C}-\text{CONR}^{25}\text{R}^{26}$ , wherein  $\text{R}^{25}$  is defined as in f), and  $\text{R}^{26}$  is defined as  $\text{R}^{25}$ , and  $\text{R}^{25}$  and  $\text{R}^{26}$  are selected independently;
- 5 i)  $\text{CH}=\text{CH}-\text{NR}^{25}\text{R}^{26}$  or  $\text{CH}=\text{CH}-\text{CONR}^{25}\text{R}^{26}$ , having a stereochemistry of E or Z, wherein  $\text{R}^{25}$  and  $\text{R}^{26}$  are independently defined as in h);
- j)  $(\text{CH}_2)_k\text{R}^{25}$ ,  $(\text{CH}_2)_k-\text{COOR}^{25}$ , or  $(\text{CH}_2)_k-\text{OR}^{25}$ , wherein k is an integer from 2 to 6 and  $\text{R}^{25}$  is defined as in f);
- k)  $(\text{CH}_2)_k\text{NR}^{25}\text{R}^{26}$ ,  $(\text{CH}_2)_k-\text{CONR}^{25}\text{R}^{26}$ , wherein  $\text{R}^{25}$  and  $\text{R}^{26}$  are selected independently, and  $\text{R}^{25}$  and  $\text{R}^{26}$  are defined as  $\text{R}^{25}$  in f);
- 10 l)  $\text{CH}_2\text{XR}^{27}$ , wherein X is O or S and  $\text{R}^{27}$  is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;
- $\text{R}^4$  is selected from the group consisting of:
- m) H, substituted or unsubstituted C(1-8) alkyl
- 15 n)



- wherein  $\text{X}=\text{O}$ , S, or NH,  $n=1$  to 4, and  $\text{R}^{51}$  is H,  $\text{R}^{52}$  and  $\text{R}^{53}$  are independently chosen from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $\text{R}^{51}$  and  $\text{R}^{52}$  are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system;
- 20  $\text{R}^5$  is selected from the group consisting of:
- o) a lone pair when  $\text{X}^5$  is N;
- and when  $\text{X}^5$  is C,  $\text{R}^5$  is selected from the group consisting of:
- p) H, substituted and unsubstituted C(1-8) alkyl;); or
- 25 q)



wherein  $X=O$ ,  $S$ , or  $NH$ ,  $n=1$  to  $4$  and  $R^{51}$  is  $H$ ,  $R^{52}$  and  $R^{53}$  are independently chosen from the group consisting of  $H$ , substituted or unsubstituted  $C(1-8)$  alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system; or


- 5 wherein in formula I, when  $A^1$  and  $A^2$ , and  $B^1$  and  $B^2$ , respectively combine to form oxygen,  $R^1-R^3$  and  $R^5-R^8$  are  $H$ , and  $R^4$  is  $H$  or  $CH_3$ , at least one of  $X^1 - X^9$  represents a ring member other than carbon.

- 10 4. A compound according to claim 1 wherein  $X^5$  is  $C$ ,  $X^{10}$  is  $CH$  and the bond between  $X^5$  and  $X^{10}$  is a double bond.

5. A compound according to claim 1 wherein  $X^5$  is  $N$ ,  $R^5$  is a lone pair,  $X^{10}$  is  $CH$  and the bond between  $X^5$  and  $X^{10}$  is a double bond.

- 15 6. A compound according to claim 1 wherein  $X^5$  is  $CH$ ,  $R^5$  is  $H$ ,  $X^{10}$  is  $CH_2$  and the bond between  $X^5$  and  $X^{10}$  is a single bond.

7. A compound according to claim 1 wherein  $R^4$  is




- 20 wherein  $X=O$ ,  $S$ , or  $NH$ ,  $n=1$  to  $4$ , and  $R^{51}$  is  $H$ ,  $R^{52}$  and  $R^{53}$  are independently chosen from the group consisting of  $H$ , alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

- 25 8. A compound according to claim 7 wherein  $R^{51 \text{ to } 53}$  are  $H$ .

9. A compound according to claim 4 wherein  $R^4$  is






wherein X=O, S, or NH, n=1 to 4, and R<sup>51</sup> is H, R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

10. A compound according to claim 9 wherein R<sup>51 to 53</sup> are H.


11. A compound according to claim 5 wherein R<sup>4</sup> is



wherein X=O, S, or NH, n=1 to 4, and R<sup>51</sup> is H, R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

12. A compound according to claim 11 wherein R<sup>51 to 53</sup> are H.

13. A compound according to claim 6 wherein R<sup>4</sup> is




wherein X=O, S, or NH, n=1 to 4, and R<sup>51</sup> is H, R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl,

substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

14. A compound according to claim 13 wherein  $R^{51}$  to  $^{53}$  are H.

5

15. A compound according to claim 4 wherein  $R^4$  is methyl and  $R^5$  is



wherein  $X=O$ ,  $S$ , or  $NH$ ,  $n=1$  to  $4$ , and  $R^{51}$  is  $H$ ,  $R^{52}$  and  $R^{53}$  are independently chosen from the group consisting of  $H$ , alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.


10

16. A compound according to claim 15 wherein  $R^{51}$  to  $^{53}$  are  $H$ .

15

17. Compounds 143, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 159, 160, 166, 167, 168, 170.

18. A compound represented by formula I as defined in claim 2 wherein  $R^4$  is methyl,  $X^5$  is carbon and  $R^5$  is




20

wherein  $X=O$ ,  $S$ , or  $NH$ ,  $n=1$  to  $4$ , and  $R^{51}$  is  $H$ ,  $R^{52}$  and  $R^{53}$  are independently chosen from the group consisting of  $H$ , alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or  $R^{51}$  and  $R^{52}$  are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

25

19. A compound according to claim 18 wherein  $R^{51-53}$  are  $H$ .


20. A compound represented by formula I as defined in claim 2 wherein R<sup>4</sup> is



wherein X=O, S, or NH, n=1 to 4, and R<sup>51</sup> is H, R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system; or

21. A compound according to claim 20 wherein R<sup>51-53</sup> are H.

22. A compound represented by formula II as defined in claim 3 wherein R<sup>4</sup> is



wherein X=O, S, or NH, n=1 to 4, and R<sup>51</sup> is H, R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

23. A compound according to claim 22 wherein R<sup>51-53</sup> are H.

24. Compounds 167 and 168.

25. A method of treatment or prevention of a condition resulting from loss of growth and cellular differentiation control, as in cancer, by administration of an effective amount of a compound according to any one of claims 1 to 24 to a patient in need thereof.

26. The method of treatment according to claim 25, wherein said compound is combined with an anti-neoplastic, an anti-neurotoxic or an antisense compound.

27. A pharmaceutical composition comprising a pharmaceutically effective amount of  
5 a compound according to any one of claims 1 to 24 in combination with a pharmaceutically acceptable carrier.

28. The pharmaceutical composition according to claim 27, additionally comprising an anti-neoplastic, an anti-neurotoxic, an anti-depressant or an antisense compound.

10

29. A method of treating cancer or inflammatory diseases comprising administering to a subject in need thereof a compound according to any one of claims 1 to 24.

30. Use of any one of compounds 133 to 142 and 169 as an anticancer agent.